Friday, July 13, 2012

Silky way to stabilize vaccines, antibiotics and drug molecule.

Researchers could effectively store mumps, and rubella (MMR) vaccines for 6 months at 25 Deg. Celsius, 37 Deg. Celsius, 45 Deg. Celsius, without losing potency and activity. Which otherwise requires a storage condition of 4 Deg. Celsius.

Silk film makes it possible to store vaccines, antibiotics, even at higher temperature which otherwise required cold storage conditions until it is delivered to patient.

Researchers at National institute of health USA have developed a silk-based stabilizer with which vaccines and antibiotic were successfully kept stable even at temperature 60 Deg. Celsius. The silk based stabilizer protected drug from effect of light as well. The silk based film can cover the biological active proteins and drug molecule protecting them from derivative effect of heat.

Therefore now it will be possible to keep the drug product and vaccines at room temperature which otherwise requires storage in cold condition in refrigeration, without losing potency and pharmacological activity of vaccines, antibiotics and drug molecules.

What is Cold chain Drugs and Cold chain distribution?

We all know that there are certain drugs, vaccines, and antibiotics which are required to be stored in cool condition and in refrigeration, Manufacturing and processing of these molecules require special cold conditions and intermediate stages too require cold environment even in the form of finished product until the product is delivered to patient so that they are protected from thermal degradation process, otherwise drug product or vaccine may render ineffective.

This entire process is also known as cold chain drug production and cold chain distribution, Cost of cold chain products is very higher just because of this factor, and the commercial losses due to not meeting storage in cool temperature in remote places too are higher , this is one of factor which makes vaccines costly.

With the new invention it will now be possible to design a unit dosage form in the silk based stabilizer which can hold the vaccine and antibiotics active even at temperature 60 Deg.Celcius.

The research is being carried out by Dr. Kaplan and his team from NIH's National Institute of Biomedical Imaging and Bioengineering (NIBIB) and Jeney Zhang, Ph.D. candidate, at Tufts University School of Engineering in Medford, Mass.

1 comment:

Unknown said...
This comment has been removed by a blog administrator.